Withdrawing medication: managing medical comorbidities near the end of life.
作者信息
O'Brien Christopher P
机构信息
Medical Director of Palliative Care Services at Horizon Health Network in Saint John, NB.
出版信息
Can Fam Physician. 2011 Mar;57(3):304-7, e89-92.
Abstract
摘要
相似文献
1
Withdrawing medication: managing medical comorbidities near the end of life.停用药物：在生命终末期管理合并症
Can Fam Physician. 2011 Mar;57(3):304-7, e89-92.
2
End-of-life care in patients with advanced lung cancer.晚期肺癌患者的临终关怀
Ther Adv Respir Dis. 2016 Oct;10(5):455-67. doi: 10.1177/1753465816660925. Epub 2016 Sep 1.
3
The Burden of Polypharmacy in Patients Near the End of Life.临终患者多重用药的负担
J Pain Symptom Manage. 2016 Feb;51(2):178-83.e2. doi: 10.1016/j.jpainsymman.2015.09.003. Epub 2015 Sep 30.
4
Managing comorbidities in patients at the end of life.管理临终患者的合并症。
BMJ. 2004 Oct 16;329(7471):909-12. doi: 10.1136/bmj.329.7471.909.
5
Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.晚期肺癌患者的姑息治疗需求报告和临终关怀的激进程度：一项基于国家登记的研究。
Cancer. 2018 Jul 15;124(14):3044-3051. doi: 10.1002/cncr.31536. Epub 2018 May 9.
6
Family member satisfaction with end-of-life decision making in the ICU.家庭成员对重症监护病房临终决策的满意度。
Chest. 2008 Mar;133(3):704-12. doi: 10.1378/chest.07-1773. Epub 2008 Jan 15.
7
Palliative care units in lung cancer in the real-world setting: a single institution's experience and its implications.真实世界中肺癌姑息治疗病房：单机构经验及其启示
Ann Palliat Med. 2017 Jan;6(1):6-13. doi: 10.21037/apm.2016.08.06. Epub 2016 Sep 1.
8
The Heidelberg Milestones Communication Approach (MCA) for patients with prognosis <12 months: protocol for a mixed-methods study including a randomized controlled trial.针对预后小于12个月患者的海德堡里程碑式沟通方法（MCA）：一项包括随机对照试验的混合方法研究方案。
Trials. 2018 Aug 14;19(1):438. doi: 10.1186/s13063-018-2814-1.
9
[A statement on palliative care in pneumology].[关于肺病姑息治疗的声明]
Dtsch Med Wochenschr. 2011 Apr;136(13):648-50. doi: 10.1055/s-0031-1274558. Epub 2011 Mar 22.
10
End-of-life decision making--have we got it right?临终决策——我们做对了吗？
Eur J Cancer Care (Engl). 2003 Sep;12(3):212-4. doi: 10.1046/j.1365-2354.2003.00408.x.
引用本文的文献
1
Pharmacists' clinical roles and activities in inpatient hospice and palliative care: a scoping review.药剂师在住院临终关怀和姑息治疗中的临床角色和活动：范围综述。
Int J Clin Pharm. 2023 Jun;45(3):577-586. doi: 10.1007/s11096-023-01535-7. Epub 2023 Feb 11.
2
Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.针对多病共存和多种药物治疗的老年人减药：TAILOR 证据综合。
Health Technol Assess. 2022 Jul;26(32):1-148. doi: 10.3310/AAFO2475.
3
Does special education in palliative medicine make a difference in end-of-life decision-making?在姑息治疗中的特殊教育是否对临终决策产生影响？
BMC Palliat Care. 2018 Jul 18;17(1):94. doi: 10.1186/s12904-018-0349-6.
4
Appropriateness of medications prescribed to elderly patients with advanced heart failure and limited life expectancy who died during hospitalization.给住院期间死亡的晚期心力衰竭且预期寿命有限的老年患者所开药物的合理性。
Drugs Aging. 2014 Jul;31(7):541-6. doi: 10.1007/s40266-014-0183-3.
本文引用的文献
1
Finding the evidence for thromboprophylaxis in palliative care: first let us agree on the question.寻找姑息治疗中血栓预防的证据：首先让我们就问题达成一致。
Palliat Med. 2010 Jun;24(4):359-61. doi: 10.1177/0269216310366389.
2
Palliative care and type II diabetes: A need for new guidelines?姑息治疗与2型糖尿病：是否需要新指南？
Am J Hosp Palliat Care. 2010 Nov;27(7):444-5. doi: 10.1177/1049909110364222. Epub 2010 Apr 13.
3
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).在低密度脂蛋白胆固醇水平低且高敏C反应蛋白升高的男性和女性中，使用瑞舒伐他汀预防首次心血管事件和死亡的需治疗人数：他汀类药物用于预防的依据：一项评估瑞舒伐他汀的干预试验（JUPITER）
Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.
4
Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation.我可以停用华法林吗？关于停用抗凝治疗的风险与益处的综述
J Palliat Med. 2009 Jan;12(1):83-7. doi: 10.1089/jpm.2008.0164.
5
Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.姑息治疗下晚期癌症患者的静脉血栓栓塞：正常临床实践中观察到的额外风险因素、一级/二级预防及并发症
Palliat Med. 2008 Dec;22(8):965-8. doi: 10.1177/0269216308098803. Epub 2008 Oct 24.
6
Withdrawal of cardiac medications and devices.停用心脏药物和器械。
AACN Adv Crit Care. 2007 Oct-Dec;18(4):415-25. doi: 10.1097/01.AACN.0000298634.45653.81.
7
Reconsidering medication appropriateness for patients late in life.重新审视老年患者用药的合理性。
Arch Intern Med. 2006 Mar 27;166(6):605-9. doi: 10.1001/archinte.166.6.605.
8
Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study.长期低分子量肝素用于姑息治疗患者的癌症相关静脉血栓栓塞治疗是否可接受？一项定性研究。
Palliat Med. 2005 Apr;19(3):197-201. doi: 10.1191/0269216305pm1008oa.
9
Managing comorbidities in patients at the end of life.管理临终患者的合并症。
BMJ. 2004 Oct 16;329(7471):909-12. doi: 10.1136/bmj.329.7471.909.
10
Dying patients in the intensive care unit: forgoing treatment, maintaining care.重症监护病房中的临终患者：放弃治疗，维持护理。
Ann Intern Med. 2000 Dec 5;133(11):886-93. doi: 10.7326/0003-4819-133-11-200012050-00013.
Zotero 插件